# Chemours Co: Form 10-Q for the period ended Mar 31, 2017

- Company: [Chemours Co](/companies/cc.md) (CIK 1627223)
- Form: 10-Q
- Filed: 2017-05-03
- Accepted by EDGAR: May 3, 2017, 15:11 ET
- Period: 2017-03-31
- Accession: 0001564590-17-008323
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1627223/000156459017008323/cc-10q_20170331.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1627223/000156459017008323/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2017-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Gross profit | 3 months, 2017-01-01 to 2017-03-31 | $358.0m | us-gaap:GrossProfit |
| Research and development | 3 months, 2017-01-01 to 2017-03-31 | $19.0m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2017-01-01 to 2017-03-31 | $144.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Interest expense | 3 months, 2017-01-01 to 2017-03-31 | $51.0m | us-gaap:InterestExpense |
| Income tax | 3 months, 2017-01-01 to 2017-03-31 | $22.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2017-01-01 to 2017-03-31 | $150.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2017-01-01 to 2017-03-31 | $0.79 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2017-01-01 to 2017-03-31 | $0.82 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2017-01-01 to 2017-03-31 | 189,149,930 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months, 2017-01-01 to 2017-03-31 | $41.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months, 2017-01-01 to 2017-03-31 | $69.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 3 months, 2017-01-01 to 2017-03-31 | $5.0m | us-gaap:PaymentsOfDividends |
| Cash and equivalents | at 2017-03-31 | $898.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2017-03-31 | $2.71bn | us-gaap:AssetsCurrent |
| Total assets | at 2017-03-31 | $6.28bn | us-gaap:Assets |
| Current liabilities | at 2017-03-31 | $1.74bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2017-03-31 | $5.92bn | us-gaap:Liabilities |
| Long-term debt | at 2017-03-31 | $3.54bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2017-03-31 | $14.0m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | at 2017-03-31 | $353.0m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 60,335 characters.

### Introduction

Management’s discussion and analysis, which we refer to as “MD&A”, of our results of operations and financial condition supplements the unaudited interim consolidated financial statements and related notes included elsewhere herein to help provide an understanding of our financial condition, changes in financial condition and results of our operations. The discussion and analysis presented below refer to and should be read in conjunction with the unaudited interim consolidated financial statements and the related notes included elsewhere in this Quarterly Report on Form 10-Q, as well as our audited consolidated financial statements and the related notes included in the Annual Report on Form 10-K for the year ended December 31, 2016.

Unless the context otherwise requires, references herein to “The Chemours Company”, “Chemours”, “the Company”, “our company”, “we”, “us”, and “our” refer to The Chemours Company and its consolidated subsidiaries. References herein to “DuPont” refer to E.I. du Pont de Nemours and Company, a Delaware corporation, and its consolidated subsidiaries (other than Chemours and its consolidated subsidiaries), unless the context otherwise requires.

### Forward-Looking Statements

This section and other parts of this Quarterly Report on Form 10-Q contain forward-looking statements, within the meaning of the federal securities law, that involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. The words “believe”, “expect”, “anticipate”, “plan”, “estimate”, “target”, “project” and similar expressions, among others, generally identify “forward-looking statements”, which speak only as of the date the statements were made.

Forward-looking statements are based on certain assumptions and expectations of future events which may not be accurate or realized. Forward-looking statements also involve risks and uncertainties, many of which are beyond Chemours’ control. Additionally, there may be other risks and uncertainties that we are unable to identify at this time or that we do not currently expect to have a material impact on our business. The matters discussed in these forward-looking statements are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those set forth in the forward-looking statements. Factors that could cause or contribute to these differences include those discussed in the “Forward-Looking Statements” and the “Risk Factors” sections in our Annual Report on Form 10-K for the year ended December 31, 2016. The Company assumes no obligation to revise or update any forward-looking statement for any reason, except as required by law.

### Overview

Chemours is a leading global provider of performance chemicals that are key inputs in end-products and processes in a variety of industries. We deliver customized solutions with a wide range of industrial and specialty chemical products for markets including plastics and coatings, refrigeration and air conditioning, general industrial and mining. Principal products include titanium dioxide (“TiO2”), refrigerants, industrial fluoropolymer resins, sodium cyanide and performance chemicals and intermediates.

Chemours manages and reports operating results through three reportable segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. Our position with each of these businesses reflects the strong value proposition we provide to our customers based on our long history and reputation in the chemical industry for safety, quality and reliability.

#### Transformation Plan

After the separation in 2015, Chemours announced a plan to transform the company by reducing structural costs, growing market positions, optimizing its portfolio, refocusing investments, and enhancing its organization. Chemours expects the transformation plan to deliver $500 million of incremental Adjusted EBITDA improvement over 2015 through 2017 based on our anticipated cost reduction and growth initiatives. We expect cost savings of approximately $350 million and approximately $150 million in improvements from growth initiatives will also improve our pre-tax earnings by similar amounts. Through year-end 2016, we realized approximately $200 million in cost savings, and we continue to implement additional cost reduction initiatives in order to realize our target additional structural costs savings of approximately $150 million, about half of which are expected to be realized in 2018. These improvements will be partially offset by the impact of divestitures completed during 2016, unfavorable price and mix of fluoropolymer products, and may also be impacted by market factors. Results of our transformation actions are further discussed in the Results of Operations, Segment Reviews and Outlook sections of this MD&A and in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016.

### Recent Developments

In April 2017, we entered into an amendment to our existing credit agreement to provide new class of term loans denominated in Euros and dollars, in an aggregate principal amount of €400 million and $940 million, respectively. The proceeds from the new class of term loans were used to repay in full the existing senior secured term loan outstanding as of March 31, 2017 of approximately $1,369 million. No incremental debt was issued as a result of the amendment. Details of the amendment are discussed further in the “Credit Facilities and Notes” section of this MD&A.

Also, in April 2017, we completed the sale of our corporate headquarters building located in Wilmington, Delaware for gross proceeds of $32 million. We will use the net proceeds from this sale to repay portion of our outstanding term loans in accordance with the credit agreement, as amended. Also, in connection with the sale, we entered into lease agreements to leaseback portion of the building beginning in April 2017. No significant gain or loss from the sale and leaseback transaction is expected to be recognized.

### Our First Quarter 2017 Results and Business Highlights

Net sales for the three months ended March 31, 2017 were $1.4 billion, an increase of 11% from $1.3 billion for the three months ended March 31, 2016. We recognized net income attributable to Chemours of $150 million and $51 million for the three months ended March 31, 2017 and 2016, respectively. Our Adjusted EBITDA was $285 million and $128 million for the three months ended March 31, 2017 and 2016, respectively. Our results for the quarter reflect improved TiO2 pricing and volume increases, and strong demand for OpteonTM, partially offset by portfolio changes in the Chemical Solutions segment.

### Results of Operations

*(Dollars in millions)*

|  | Three Months Ended March 31, 2017 | 2016 |
| --- | ---: | ---: |
| Net sales | $1,437 | $1,297 |
| Cost of goods sold | 1,079 | 1,095 |
| Gross profit | 358 | 202 |
| Selling, general and administrative expense | 144 | 133 |
| Research and development expense | 19 | 23 |
| Restructuring and asset-related charges, net | 12 | 17 |
| Total expenses | 175 | 173 |
| Equity in earnings of affiliates | 7 | 5 |
| Interest expense, net | (51) | (57) |
| Other income, net | 34 | 93 |
| **Income before income taxes** | 173 | 70 |
| Provision for income taxes | 22 | 19 |
| **Net income** | 151 | 51 |
| Less: Net income attributable to noncontrolling interests | 1 | — |
| **Net income attributable to Chemours** | $150 | $51 |

### Net Sales

Net sales for the three months ended March 31, 2017 were $1.4 billion, an increase of approximately 11% compared to $1.3 billion in the same period in 2016. The increase in net sales for the three months ended March 31, 2017 was driven by volume increases in the Titanium Technologies and Fluoroproducts segments of approximately 15%, and price improvements in TiO2 contributed to an approximately 5% increase in net sales. These increases were partially offset by portfolio changes in the Chemicals Solutions segment and approximately 1% unfavorable foreign currency impact.

The table below shows the impact of price, volume, currency and portfolio changes on net sales for the three months ended March 31, 2017 compared with the three months ended March 31, 2016:

30

### The Chemours Company

| Change in net sales from prior period | Three Months Ended March 31, 2017 |
| --- | ---: |
| Price | 5% |
| Volume | 15% |
| Currency | (1)% |
| Portfolio / Other | (8)% |
| Total Change | 11% |

For a detailed discussion of net sales, see the Segment Reviews section of this MD&A.

### Cost of goods sold

Cost of goods sold (COGS) decreased by 1% for the three months ended March 31, 2017 when compared to the same period in 2016, primarily driven by portfolio changes in our Chemical Solutions segment which decreased COGS by approximately 9%, partially offset by sales volume increases in line with sales increases in the first quarter of 2017.

### Selling, general and administrative expense

Selling, general and administrative (SG&A) expense increased by 8% to $144 million for the three months ended March 31, 2017 from $133 million for the three months ended March 31, 2016. Increase in SG&A was due to higher accrual related to performance related compensation by approximately $6 million, additional water treatment accruals related to PFOA of approximately $3 million and higher legal costs incurred in connection with the PFOA MDL settlement.

### Research and development expense

Research and development (R&D) expense decreased by $4 million to $19 million for the three months ended March 31, 2017 from $23 million for the three months ended March 31, 2016. The decrease in R&D expense was driven by decisions to focus on fewer, higher return projects.

### Restructuring and asset-related charges, net

We recorded pre-tax charges of approximately $12 million for employee separation, decommissioning and other asset-related charges for the three months ended March 31, 2017 compared to $17 million for the three months ended March 31, 2016.

Charges for the three months ended March 31, 2017 consist primarily of decommissioning and dismantling activities related to the closure of the Edge Moor manufacturing plant in the Titanium Technologies segment of approximately $4 million, closure of certain production lines in the Fluoroproducts segment of approximately $3 million, and closure of reactive metals solution (“RMS”) manufacturing plant in the Chemical Solutions segment of approximately $5 million.

Charges for the three months ended March 31, 2016 consist primarily of $8 million related to our Edge Moor manufacturing plant decommissioning and dismantling activities in our Titanium Technologies segment and $4 million related to decommissioning activities of certain production lines in our Fluoroproducts segment. We also incurred an additional $4 million of employee separation costs due to continued efforts to streamline and simplify our organizational structure and to reduce costs.

For details related to “Restructuring and asset-related charges, net”, see Note 3 to the Interim Consolidated Financial Statements.

### Interest expense, net

We incurred interest expense of $51 million for the three months ended March 31, 2017 compared to $57 million for the three months ended March 31, 2016. Interest expense decreased by approximately $6 million for the three months ended March 31, 2017 due to lower outstanding debt principal as a result of debt repurchases and repayments that occurred from mid-2016 through year-end. In addition, interest expense for the three months ended March 31, 2016 includes approximately $4 million of non-cash write-off of unamortized debt issuance costs attributable to the reduction in our revolver commitment, which did not recur in 2017. These decreases were slightly offset by lower capitalized interest in the three months ended March 31, 2017 versus the three months ended March 31, 2016 due to our Altamira plant expansion that was completed in the second of quarter of 2016.

### Other income, net

Other income, net decreased by $59 million to $34 million for the three months ended March 31, 2017 from $93 million for the three months ended March 31, 2016. The decrease was primarily due to $89 million of gain recognized from the sale of our aniline facility in Beaumont, Texas to Dow in the first quarter of 2016 that did not recur in 2017, partially offset by a $16 million gain on sale recognized in the first quarter of 2017 primarily related to the sale of the Edge Moor site and other asset sales. In addition, other income primarily includes foreign currency exchange gain of $5 million in the first quarter of 2017 compared to foreign currency exchange losses of $6 million in 2016, which was mainly driven by weakening of the U.S. dollar against Mexican peso during the first quarter of 2017.

For additional details on other income, net and foreign currency forward contracts, see Note 4 and Note 14 to the Interim Consolidated Financial Statements, respectively.

### Provision for income taxes

For the three months ended March 31, 2017 and 2016, Chemours recorded a provision for income tax of $22 and $19, respectively, resulting in an effective income tax rate of approximately 13% and 27%, respectively. The income tax provision for the three months ended March 31, 2017 is inclusive of a $10 income tax benefit from stock option windfalls. The income tax provision for the three months ended March 31, 2016 is inclusive of $34 income tax expense related to fixed asset sales that took place during the quarter. The remaining change in the effective tax rate from the prior year is primarily due to the Company’s geographical mix of earnings as well as the impact of the additional valuation allowance on U.S. foreign tax credits of approximately $5 million during the first quarter of 2017, from which the Company does not expect to benefit in 2017.

### Segment Reviews

The following table represents Chemours’ total consolidated Adjusted EBITDA by segment:

*(Dollars in millions)*

|  | Three Months Ended March 31, 2017 | 2016 |
| --- | ---: | ---: |
| Titanium Technologies | $159 | $54 |
| Fluoroproducts | 155 | 85 |
| Chemical Solutions | 12 | 10 |
| Corporate and Other | (41) | (21) |
| Total | $285 | $128 |

Corporate costs and certain legal and environmental expenses that are not allocated to the segments are reflected in Corporate and Other. The increase in Corporate and Other costs primarily relates to higher performance-related compensation expense and higher legal costs incurred in connection with the PFOA MDL settlement.

Adjusted EBITDA represents our primary measure of segment performance and is defined as income before income taxes excluding the following:

- interest expense, depreciation and amortization,
- non-operating pension and other postretirement employee benefit costs, which represent the component of net periodic pension costs (income) excluding service cost component,
- exchange losses (gains) included in “other income, net” of the statement of operations,
- restructuring, asset-related charges and other charges, net,
- asset impairments,
- losses (gains) on sale of business or assets, and
- other items not considered indicative of our ongoing operational performance and expected to occur infrequently.

A reconciliation of Adjusted EBITDA to net income for the three months ended March 31, 2017 and 2016 is included in the Non-GAAP Financial Measures in this Item 2 and in Note 17 to the Interim Consolidated Financial Statements.

### Titanium Technologies

*(Dollars in millions)*

|  | Three Months Ended March 31, 2017 | 2016 |
| --- | ---: | ---: |
| Segment Net Sales | $646 | $521 |
| Adjusted EBITDA | 159 | 54 |
| Adjusted EBITDA Margin | 25% | 10% |

32

### The Chemours Company

| Change in segment net sales from prior period | Three Months Ended March 31, 2017 |
| --- | ---: |
| Price | 14% |
| Volume | 11% |
| Currency | (1)% |
| Portfolio / Other | —% |
| Total Change | 24% |

***Segment Net Sales:*** Net sales increased by 24% for the three months ended March 31, 2017 when compared with the same period in 2016. The increase in net sales was primarily due to improvement in global average selling prices from 2016 through 2017 and volume increase. The global average selling price of our TiO2 in the first quarter of 2017 is approximately 12% higher than the global average selling price in the first quarter of 2016. Our TiO2 sales volume also increased in the first quarter by approximately 13% due to the higher demand and tight supply in all regions. Unfavorable foreign currency impact, primarily due to strengthening of U.S. dollar against the Euro, contributed to 1% decrease in net sales.

***Adjusted EBITDA and Adjusted EBITDA margin:*** Adjusted EBITDA and Adjusted EBITDA margin increased by $105 million (or 194%) and 15%, respectively, during the three months ended March 31, 2017 when compared to the same period in 2016. These increases were primarily driven by selling price and volume increases, which increased Adjusted EBITDA by approximately 178%. Production efficiency improvements also contributed to increase in Adjusted EBITDA by approximately 30%. These increases were partially offset by unfavorable foreign currency impact of approximately 10% primarily due to strengthening of U.S. dollar against the Euro.

### Fluoroproducts

*(Dollars in millions)*

|  | Three Months Ended March 31, 2017 | 2016 |
| --- | ---: | ---: |
| Segment Net Sales | $652 | $531 |
| Adjusted EBITDA | 155 | 85 |
| Adjusted EBITDA Margin | 24% | 16% |

| Change in segment net sales from prior period | Three Months Ended March 31, 2017 |
| --- | ---: |
| Price | (1)% |
| Volume | 24% |
| Currency | —% |
| Portfolio / Other | —% |
| Total Change | 23% |

***Segment Net Sales:*** Net sales increased by 23% for the three months ended March 31, 2017 in comparison with the same period in 2016. Continued strong demand for Opteon™ refrigerant in Europe and the United States delivered a significant increase in volume over the prior period along with slightly higher fluoropolymer product volume. These increases were partially offset by lower selling prices for fluoropolymer products due to competitive pricing pressures.

***Adjusted EBITDA and Adjusted EBITDA margin:*** Adjusted EBITDA and Adjusted EBITDA margin increased by $70 million (or 82%) and 8%, respectively, during the three months ended March 31, 2017 when compared to the same period in 2016. These increases were due primarily to strong sales demand in fluorochemicals. Margin improvement from fluorochemicals sales contributed an increase of approximately 76%. Remaining variance was contributed by higher fluoropolymer product volume, partially offset by lower price driven by unfavorable mix.

The Fluoroproducts segment continues to evaluate its cost structure to optimize the segment’s profitability. It is possible that we may incur additional charges from this action.

### Chemical Solutions

*(Dollars in millions)*

|  | Three Months Ended March 31, 2017 | 2016 |
| --- | ---: | ---: |
| Segment Net Sales | $139 | $245 |
| Adjusted EBITDA | 12 | 10 |
| Adjusted EBITDA Margin | 9% | 4% |

| Change in segment net sales from prior period | Three Months Ended March 31, 2017 |
| --- | ---: |
| Price | —% |
| Volume | 1% |
| Currency | —% |
| Portfolio / Other | (44)% |
| Total Change | (43)% |

***Segment Net Sales:*** Net sales decreased by 43% in the three months ended March 31, 2017 compared with the same period in 2016 primarily due to portfolio changes resulting from the sale of our aniline facility in Beaumont, Texas, our Clean & Disinfect business and our Sulfur business in 2016, which represents approximately 44% decrease net sales. This was partially offset by modest sales volume increase in our performance chemicals & intermediate products.

***Adjusted EBITDA and Adjusted EBITDA margin:*** Adjusted EBITDA and Adjusted EBITDA margin increased by $2 million (or 20%) and 5% in the three months ended March 31, 2017 when compared to the same period in 2016. The improvement in Adjusted EBITDA and Adjusted EBITDA margin reflect lower operating costs of approximately $9 million from cost reduction initiatives including production shutdown at our RMS site in Niagara Falls, New York and margin improvements in our Performance Chemicals & Intermediates business. These increases were partially offset by the impacts of the divestitures.

### 2017 Outlook

For the remainder of the year, we continue to anticipate that the Company’s performance will remain strong for both Ti-Pure™ TiO2 and Opteon™ refrigerants. We expect to deliver full-year Adjusted EBITDA improvement, with similar pre-tax income improvement, substantially in line with our transformation goals. We are committed to delivering additional structural cost savings of approximately $150 million and we continue to implement certain initiatives in order to realize our target cost savings, about half of which are expected to be realized in 2018. We also expect to generate positive free cash flow for the full-year 2017 excluding payments relating to the PFOA MDL settlement. Our outlook reflects our current visibility and expectations on market factors, such as currency movements, TiO2 pricing, end-market demand and seasonality.

### Liquidity & Capital Resources

Chemours’ primary source of liquidity is cash generated from operations, available cash and borrowings under debt financing arrangements. We believe these sources are sufficient to fund our planned operations and to meet our interest, dividend and contractual obligations. Our financial policy seeks to deleverage by using free cash flow to repay outstanding borrowings, selectively invest for growth to enhance our portfolio including certain strategic capital investments, and return cash to shareholders through dividend payments and possible share repurchases in the future. Subject to approval, we may raise additional capital or borrowings from time to time. However, there can be no assurance that future capital or borrowings will be available to us, and that the cost and availability of new capital or borrowings could be materiality impacted by market conditions.

Over the next 12 months, Chemours expects to have significant interest, capital expenditures, PFOA MDL settlement, restructuring and dividend payments. We expect to fund these payments through cash generated from operations, available cash and borrowings. We anticipate that our operations and debt financing arrangements will provide sufficient liquidity over the next 12 months. Availability under our revolving credit facility is subject to the last 12 months of our consolidated EBITDA as defined under the credit agreement.

As of March 31, 2017 and December 31, 2016, we had $701 million and $678 million, respectively, of cash and cash equivalents on our balance sheet held by our foreign subsidiaries, all of which is readily convertible into currencies used in our operations, including the U.S. dollar. Cash and earnings of our foreign subsidiaries are generally used to finance their operations and capital expenditures. At March 31, 2017 and December 31, 2016, management believed that sufficient liquidity was available in the United States, and it is our intention to indefinitely reinvest undistributed earnings of our foreign subsidiaries outside of the United States. No deferred tax liabilities have been recognized with regard to the approximately $701 million and $678 million of cash and cash equivalents of our foreign subsidiaries as of March 31, 2017 and December 31, 2016, respectively, and undistributed earnings. The potential tax implications of the repatriation of unremitted earnings are driven by facts at the time of distribution. Therefore, it is not practicable to estimate the income tax liabilities that might be incurred if such cash and earnings were repatriated to the United States.

### Cash Flows

The following table sets forth a summary of the net cash provided by (used for) operating, investing and financing activities.

*(Dollars in millions)*

|  | Three Months Ended March 31, 2017 | 2016 |
| --- | ---: | ---: |
| Cash provided by operating activities | $41 | $36 |
| Cash (used for) provided by investing activities | (63) | 50 |
| Cash provided by (used for) financing activities | 11 | (16) |

#### Operating Activities

Cash provided by operating activities increased by $5 million for the three months ended March 31, 2017 when compared to the same period in 2016. First quarter of 2016 included an advance payment of $190 million that we received from DuPont in February 2016, of which approximately $15 million and $166 million were outstanding as of March 31, 2017 and 2016. Excluding the advance payment in 2016, cash provided by operating activities improved significantly due to favorable increases in our operating results in the first quarter of 2017 when compared in the first quarter of 2016.

#### Investing Activities

Cash used for investing activities for the three months ended March 31, 2017 primarily relates to capital expenditures made during the period of approximately $69 million. The three months ended March 31, 2016 includes $140 million proceeds from the sale of our aniline facility in Beaumont, Texas, which did not recur in 2017, partially offset by capital expenditures during the period of $89 million. Our capital expenditures decreased by approximately $20 million when compared to the same period in 2016 due to lower spending primarily from the completion of our Altamira plant expansion in April 2016.

We expect our full year capital expenditures in 2017 to approach $450 million, which is above our annual capital expenditures in 2016, primarily due to expenditures associated with our new OpteonTM plant under construction in Corpus Christi and our anticipated Mining Solutions expansion, which is expected to begin in the second half of 2017.

#### Financing Activities

In the first quarter of 2017, and consistent with the first quarter 2016, we had quarterly required repayments on the senior secured term loans equivalent to 1% per annum of its original principal, and also declared and paid approximately $5 million of dividends to our shareholders, equivalent to $0.03 per share. These were offset by cash received of approximately $20 million from exercise of stock options during the period. No similar options were exercised in the first quarter of 2016.

In April 2017, we completed an amendment to our credit agreement that provided for new class of term loans, i.e. Dollar Term Loan of $940 million and Euro Term Loan of €400 million. The New Term Loans replaced the existing senior secured term loan outstanding as of March 31, 2017 of approximately $1,369 million, of which $940 million was a made through a cashless settlement of the Dollar Term Loan issuance, and the remaining $429 million was funded through a Euro Term Loan issuance. Details of the amendment are discussed further below in the “Credit Facilities and Notes” section of this MD&A.

### Current Assets

*(Dollars in millions)*

|  | March 31, 2017 | December 31, 2016 |
| --- | ---: | ---: |
| Cash and cash equivalents | $898 | $902 |
| Accounts and notes receivable - trade, net | 921 | 807 |
| Inventories | 822 | 767 |
| Prepaid expenses and other | 70 | 77 |
| Total current assets | $2,711 | $2,553 |

35

Accounts and notes receivable - trade, net at March 31, 2017 increased by $114 million compared to December 31, 2016 primarily due to higher sales in the first quarter of 2017 over fourth quarter of 2016 and favorable currency translation impact of approximately $10 million.

Inventories at March 31, 2017 increased $55 million compared to December 31, 2016 due to inventory build for increasing sales demand, primarily in the Titanium Technologies segment, and favorable currency translation impact of approximately $11 million.

### Current Liabilities

*(Dollars in millions)*

|  | March 31, 2017 | December 31, 2016 |
| --- | ---: | ---: |
| Accounts payable | $941 | $884 |
| Current maturities of long-term debt | 14 | 15 |
| Other accrued liabilities | 780 | 872 |
| Total current liabilities | $1,735 | $1,771 |

As of March 31, 2017, accounts payable increased by $57 million compared to December 31, 2016 due to higher inventories and timing of payments to vendors.

Other accrued liabilities decreased by $92 million due to utilization of DuPont prepayment of approximately $43 million, severance payments of approximately $12 million and payment of performance related compensation in March 2017. These increases were partially offset by approximately $37 million increase in accrued interest due to the timing of the senior unsecured notes (the “Notes”) payments which are scheduled in May and November of each year.

### Credit Facilities and Notes

Our credit agreement, as amended, includes a seven-year senior secured term loan (the “Term Loan”) and a five-year $750 senior secured revolving credit facility (the “Revolving Credit Facility”). The proceeds of loans made under the Revolving Credit Facility can be used to finance capital expenditures, acquisitions, working capital needs and for other general corporate purposes. Availability under the Revolving Credit Facility is subject to certain covenant limitations. At March 31, 2017, the facility had a full borrowing capacity of $750 million, from which we had $123 million of letters of credit issued and outstanding under this facility.

On April 3, 2017, we completed an amendment (the “April 2017 Amendment”) to our credit agreement, which provides for a new class of term loans, denominated in Euros, in an aggregate principal amount of €400 million (the “Euro Term Loan”), and a new class of term loans, denominated in dollars, in an aggregate principal amount of $940 million (the “Dollar Term Loan”, and, collectively with the Euro Term Loan, the “New Term Loans”). The New Term Loans replaced in full the existing Term Loan (the “Existing Term Loans”) outstanding as of March 31, 2017 of approximately $1,369 million. The New Term Loans mature on May 12, 2022, which is the same maturity date of the Existing Term Loans. The Euro Term Loan bears a variable interest rate equal to EURIBOR plus 2.25% subject to a EURIBOR floor of 0.75% and the Dollar Term Loan bears a variable interest rate equal to LIBOR plus 2.50% subject to a LIBOR floor of 0.00%. The April 2017 Amendment also modifies certain provisions of the credit agreement, including increasing certain incurrence limits to allow further flexibility for the Company. All other provisions, including financial covenants, remains unchanged. No incremental debt was issued as a result of the April 2017 Amendment, although the Euro Term Loan will be subject to remeasurement gains or losses. We expect to record approximately $3 million of loss on debt extinguishment and related fees in the second quarter of 2017.

The credit agreement, as amended, contains financial covenants which, solely with respect to the revolving credit facility, require us not to exceed a maximum senior secured net leverage ratio of 3.50 to 1.00 each quarter through December 31, 2016, 3.00 to 1.00 through June 30, 2017 and further decreasing by 0.25 to 1.00 every subsequent six months to 2.00 to 1.00 by January 1, 2019 and thereafter. We are also required to maintain a minimum interest coverage ratio of 1.75 to 1.00 each quarter through June 30, 2017 and further increasing by 0.25 to 1.00 every subsequent six months to 3.00 to 1.00 by January 1, 2019 and thereafter. In addition, the credit agreement contains customary affirmative and negative covenants that, among other things, limit or restrict us and our subsidiaries’ ability, subject to certain exceptions, to incur liens, merge, consolidate or sell, transfer or lease assets, make investments, pay dividends, transact with subsidiaries and incur indebtedness. The credit agreement also contains customary representations and warranties and events of default. The senior secured credit facilities and the Notes contain events of default customary for these types of financings, including cross default and cross acceleration provisions to material indebtedness of Chemours. We were in compliance with our debt covenants as of March 31, 2017.

In the event of default under the revolving credit facility, our lenders under the revolving credit facility can terminate their commitments thereunder, cease making further revolving loans and accelerate outstanding revolving loans. This would allow the lenders under the revolving credit facility to declare the outstanding term loans to be immediately due and payable and to institute foreclosure proceedings against the collateral securing the credit facility, which could force us into bankruptcy or liquidation. Any event of default or declaration of acceleration under the credit agreement also may result in an event of default under the indenture governing the notes. Any such default, event of default or declaration of acceleration could materially and adversely affect our results of operations and financial condition. Please see the section titled “Risks Related to Our Indebtedness” of the “Risk Factors” section of our Annual Report Form 10-K for the year ended December 31, 2016 for additional detail.

For the remainder of 2017, under the April 2017 Amendment, we are required to make principal payments related to the New Term Loans of approximately $10 million and approximately $14 million in each year from 2018 to 2021. Debt maturities related to the New Term Loans and the Notes in 2022 and beyond will be $3,529 million. In addition, following the end of each fiscal year commencing on the year ended December 31, 2016, we are also required to make additional principal repayments, depending on our leverage level as defined in the credit agreement, equivalent to up to 50% of excess cash flow based on certain leverage targets with stepdowns to 25% and 0% as actual leverage decreases to below the 3.00 to 1.00 leverage target. No principal repayments were required to be made in the first quarter of 2017 based upon the December 31, 2016 excess cash flow determined under the credit agreement. See Note 12 to the Interim Consolidated Financial Statements included in this Quarterly Report on Form 10-Q for additional information related to our indebtedness.

### Supplier Financing

In 2015, we entered into a global paying services agreement with a financial institution. Under this agreement, the financial institution acts as the paying agent for Chemours with respect to accounts payable due to our suppliers who elect to participate in the program. The agreement allows our suppliers to sell their receivables to the financial institution at the discretion of both parties on terms that are negotiated between them. Our obligations to our suppliers, including the amounts due and scheduled payment dates, are not impacted by our suppliers’ decisions to sell their receivables under this program. At March 31, 2017, the payment instructions from Chemours were $128 million. Pursuant to their agreement with the financial institution, certain suppliers may elect to get paid early at their discretion. The available capacity under this program can vary based on the number of investors participating in this program at any point in time.

### Contractual Obligations

Information related to the Company’s contractual obligations is summarized below:

*(Dollars in millions)*

|  | Total at March 31, 2017 | Payments Due In Remainder of 2017 | 2018 - 2019 | 2020 - 2021 | 2022 and Beyond |
| --- | ---: | ---: | ---: | ---: | ---: |
| Long-term debt obligations 1 | $3,595 | $39 | $27 | $27 | $3,502 |
| Interest payments on long-term debt obligations 1 | 1,244 | 146 | 385 | 383 | 330 |
| Operating leases | 244 | 47 | 99 | 55 | 43 |
| Purchase obligations 2 |  |  |  |  |  |
| Raw material obligations | 1,220 | 73 | 153 | 144 | 850 |
| Utility obligations | 649 | 74 | 143 | 129 | 303 |
| Other | 110 | 42 | 55 | 13 | 0 |
| Total purchase obligations | 1,979 | 189 | 351 | 286 | 1,153 |
| Other liabilities |  |  |  |  |  |
| Workers’ compensation | 34 | 4 | 15 | 7 | 8 |
| Asset retirement obligations | 43 | 2 | 2 | — | 39 |
| Environmental remediation | 279 | 68 | 113 | 51 | 47 |
| Legal settlements 3 | 351 | 338 | 5 | 5 | 3 |
| Employee separation costs | 22 | 19 | 3 | — | — |
| Other 4 | 51 | 24 | 4 | 4 | 19 |
| Total other liabilities | 780 | 455 | 142 | 67 | 116 |
| Total contractual obligations 5 | $7,842 | $876 | $1,004 | $818 | $5,144 |

37

1 In April 2017, the Company entered into an amendment to its credit agreement, further described in the “Credit Facilities and Notes” section of this MD&A. Principal and interest payments reflect the amended terms of the new term loans. Interest rates and foreign exchange rates reflect the prevailing rates as of March 31, 2017. No incremental debt was incurred as a result of the April 2017 Amendment, although the Euro Term Loan will be subject to remeasurement gains or losses. Also, an estimated net proceeds of approximately $29 million, subject to customary adjustments, from the sale of our corporate headquarters building were included as principal repayment in 2017, required under the credit agreement as amended.

2 Represents enforceable and legally binding agreements to purchase goods or services that specify fixed or minimum quantities; fixed minimum or variable price provisions; and the approximate timing of the agreement.

3 Includes $335 million litigation accrual related to the PFOA MDL Settlement (see Note 13 to the Interim Consolidated Financial Statements).

4 Includes expected contributions and benefits payments in excess of plan assets to be made to fund our pension and other long-term employee benefit plans. Actual payments will depend on several factors, including investment performance and discount rates, and may also be affected by changes in applicable local requirements. See Note 22 to the Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2016 for additional information.

5 Due to uncertainty regarding the completion of tax audits and possible outcomes, we are unable to determine the timing of payments related to unrecognized tax benefits. See Note 9 to the Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2016 for additional information.

### Off Balance Sheet Arrangements

Information with respect to Chemours’ guarantees is included Note 20 to the Consolidated Financial Statements in the Annual Report on Form 10-K for the year ended December 31, 2016. Historically, Chemours has not made significant payments to satisfy guarantee obligations; however, Chemours believes it has the financial resources to satisfy these guarantees in the event required. Remaining guarantees outstanding as of March 31, 2017 was insignificant.

### Critical Accounting Policies and Estimates

Chemours’ significant accounting policies are described in “Management's Discussion and Analysis of Financial Condition and Results of Operations - Critical Accounting Policies and Estimates” and Note 3 to the Consolidated Financial Statements in our Annual Report on Form 10-K. There have been no material changes to our critical accounting policies and estimates previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2016.

### Recent Accounting Pronouncements

See Note 2 to the Interim Consolidated Financial Statements included in this Quarterly Report on Form 10-Q for discussions of recent accounting pronouncements.

### Environmental Matters

Consistent with our Chemours values and our Environment, Health and Safety (EHS) Policy, Chemours is committed to preventing releases to the environment at our manufacturing sites to keep our people and communities safe and to be good stewards of the environment. Chemours is also subject to environmental laws and regulations relating to the protection of the environment. We believe that, as a general matter, our policies, standards and procedures are properly designed to prevent unreasonable risk of harm to people and the environment, and that our handling, manufacture, use and disposal of hazardous substances are in accordance with applicable environmental laws and regulations.

### Environmental Remediation

Mainly because of past operations, operations of predecessor companies or past disposal practices, we, like many other similar companies, have clean-up responsibilities, associated remediation costs and are subject to claims by other parties, including claims for matters that are liabilities of DuPont and its subsidiaries that Chemours may be required to indemnify pursuant to the separation-related agreements executed prior to the separation.

Our environmental reserve includes estimated costs related to a number of sites for which it is probable that environmental remediation will be required, whether or not subject to enforcement activities, as well as those obligations that result from environmental laws such as the Comprehensive Environmental Response, Compensation and Liability Act (CERCLA, often referred to as Superfund), the Resource Conservation and Recovery Act (RCRA) and similar state, federal and foreign laws. These laws require certain investigative, remediation and restoration activities at sites where Chemours conducts or once conducted operations or at sites where Chemours-generated waste was disposed. At March 31, 2017 and December 31, 2016, we recorded environmental remediation accruals of $279 and $278 million, respectively, which, in management’s opinion, is appropriate based on existing facts and circumstances.

Our remediation portfolio is relatively mature, with many of our sites under active clean-up moving towards final completion. As remediation efforts progress, sites move from the investigation phase (Investigation) to the active clean-up phase, and as construction is completed at active clean-ups (Active Remediation), those sites move to the ongoing maintenance and monitoring (OM&M) or closure phase. As final clean-ups for some significant sites are completed over the next several years, we expect our annual expenses related to these active sites to decline over time. The time-frame for a site to go through all phases of remediation (investigation and active clean-up) may take about 15 to 20 years, followed by several years of OM&M activities. Remediation activities, including OM&M activities, vary substantially in duration and cost from site to site. These activities, and their associated costs, depend on the mix of unique site characteristics, evolving remediation technologies, diverse regulatory requirements, as well as the presence or absence of other potentially responsible parties. In addition, for claims that Chemours may be required to indemnify DuPont pursuant to the separation-related agreements, Chemours, through DuPont, has limited available information for certain sites or is in the early stages of discussions with regulators. For these sites in particular, there may be considerable variability between the clean-up activities that are currently being undertaken or planned and the ultimate actions that could be required. Therefore, considerable uncertainty exists with respect to environmental remediation costs and, under adverse changes in circumstances, although deemed remote, the potential liability may range up to approximately $480 million above the amount accrued at March 31, 2017. In general, uncertainty is greatest and the range of potential liability is widest in the investigation phase, and narrows over time as regulatory agencies approve site remedial plans, uncertainty is reduced and, ultimately, sites move into OM&M, where needed. As more sites advance from investigation to active clean-up to OM&M or closure, the upper end of the range of potential liability is expected to decrease over time.

Some remediation sites will achieve site closure and will require no further action to protect people and the environment and comply with laws and regulations. At certain sites, we expect that there will continue to be some level of remediation activity due to ongoing monitoring and/or operations & maintenance of remedial systems. In addition, portfolio changes such as an acquisition or divestiture or notification as a potentially responsible party for a multi-party Superfund site could result in additional remediation activity and potentially additional accrual.

Management does not believe that any loss, in excess of amounts accrued, related to remediation activities at any individual site will have a material impact on our financial position, results of operations or cash flows in any given year, as such obligation can be satisfied or settled over many years. For additional information, refer to the Environmental Matters section of Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the year ended December 31, 2016.

While there are many remediation sites that contribute to the total environmental remediation accrual, the following sites are among the most significant:

*(Dollars in millions)*

|  | March 31, 2017 | December 31, 2016 |
| --- | ---: | ---: |
| Beaumont, Texas | $12 | $12 |
| Chambers Works, New Jersey | 24 | 24 |
| East Chicago, Indiana | 20 | 20 |
| Pompton Lakes, New Jersey | 76 | 77 |
| USS Lead, East Chicago, Indiana | 24 | 21 |
| All Other Sites | 123 | 124 |
| Balance at December 31 | $279 | $278 |

The five sites listed above represent more than 50% of our reserve and we expect to spend, in aggregate, approximately $104 million over the next three years. For all other sites, we expect to spend approximately $71 million over the next three years.

#### Beaumont Works, Beaumont, Texas

Beaumont Works began operations in 1954 in Beaumont, Jefferson County, Texas. Over the years, Beaumont Works has produced a number of basic chemicals and elastomer products including acrylonitrile, ammonia, methanol, methyl methacrylate, caprolactam, Hypalon® synthetic rubber, Nordel® hydrocarbon rubber and blended tetraethyl lead with halo-carbon solvent/stabilizers. As of March 31, 2017, with sale of the aniline production unit to Dow in 2016, Chemours has no on-going manufacturing operations on the site. Dow and Lucite remain as long-term manufacturing tenants.

As site owner, Chemours remains responsible for remediation of historical chemical releases from past operations and is conducting this work under a RCRA hazardous waste post-closure permit and Compliance Plan (CP) issued by the State of Texas. The hazardous waste permit includes provisions to manage wastes and to investigate and mitigate releases. The CP is a component of the permit and includes mitigation and monitoring requirements, including a groundwater remediation system that was installed in 1991 to control chemical migration and protect adjacent water bodies. In addition, several solid waste management unit closures have been conducted and areas of past release addressed through interim measures to protect people and the environment. Over the years, extensive site studies have been completed and a final investigation report (Affected Property Assessment Report, or APAR, under the Texas Risk Reduction Program) for the entire site was approved by the State in 2014. Chemours has recently completed a remedial action plan (RAP), currently under agency review, to address all remaining historical solid waste management units and areas of concern identified in these studies, and expects to have this RAP approved in 2017.

The remediation accrual for Beaumont addresses remaining work identified in the RAP under review by the State as well as post-closure care and monitoring and on-going operation of the groundwater remediation system. A portion of the accrual also addresses an outstanding Natural Resource Damage claim by state and federal trustees directed to impacts on marshlands within the plant property.

#### Chambers Works, Deepwater, New Jersey

The Chambers Works complex is located on the eastern shore of the Delaware River in Deepwater, Salem County, New Jersey. The site comprises the former Carneys Point Works in the northern area and the Chambers Works manufacturing area in the southern area. Site operations began in 1892 when the former Carneys Point smokeless gunpowder plant was constructed at the northern end of Carneys Point. Site operations began in the manufacturing area around 1914 and included the manufacture of dyes, aromatics, elastomers, CFCs, and tetraethyl lead. Chemours continues to manufacture a variety of fluorochemicals and finished products at Chambers Works. In addition, three tenants operate processes at Chambers Works including steam/electricity generation, industrial gas production and the manufacture of intermediate chemicals. As a result of over 100 years of continuous industrial activity, site soils and groundwater have been impacted by chemical releases.

In response to identified groundwater contamination, a groundwater interceptor well system (IWS) was installed in 1970, which was designed to contain contaminated groundwater and restrict off-site migration. Additional remediation is being completed under a Federal RCRA Corrective Action Permit. The site has been studied extensively over the years and more than 25 remedial actions have been completed to date and engineering and institutional controls put in place to ensure protection of people and the environment.

Remaining work beyond continued operation of the IWS and groundwater monitoring includes completion of a site perimeter sheet pile barrier intended to more efficiently contain groundwater, completion of various targeted studies onsite and in adjacent water bodies to close investigation data gaps, and selection and implementation of final remedies under RCRA Corrective Action for various solid waste management units and areas of concern not yet addressed through interim measures.

#### East Chicago, Indiana

East Chicago is a former manufacturing facility owned by Chemours in East Chicago, Lake County, Indiana. The approximately 440-acre site is bounded to the south by the East Branch of the Grand Calumet River, to the east and north by residential and commercial areas, and to the west by industrial areas, including a former lead processing facility. The inorganic chemicals unit on site produced various chloride, ammonia, and zinc products and inorganic agricultural chemicals beginning in 1892 until 1986. Organic chemical manufacturing began in 1944, consisting primarily of chlorofluorocarbons production. Current operations, including support activities, now cover 28 acres of the Site. The remaining business was sold to W.R. Grace Company (Grace) in early 2000, and Grace operates the unit as a tenant. Approximately 172 acres of the site were never developed and are managed by The Nature Conservancy for habitat preservation.

A comprehensive evaluation of soil and groundwater conditions at the Site was performed as part of the RCRA corrective action process. Studies of historical site impacts began in 1983 in response to preliminary CERCLA actions undertaken by the U.S Environmental Protection Agency (EPA). The EPA eventually issued an Administrative Order on Consent for the Site in 1997. The order specified that remediation work be performed under RCRA Corrective Action authority. Work has proceeded under the RCRA Corrective Action process since that time.

Subsequent investigations included the preparation of initial environmental site assessments and multiple phases of investigation. In 2002, as an interim remedial measure, two 2,000-foot-long permeable reactive barrier treatment walls were installed along the northern property boundary to address migration of chemicals in groundwater. Since that time, the investigation process has been completed and approved by the EPA and work is in progress to define the final remedy for the site.

#### Pompton Lakes, New Jersey

During the twentieth century, blasting caps, fuses and related materials were manufactured at Pompton Lakes, Passaic County, New Jersey. Operating activities at the site were ceased in the mid-1990s. Primary contaminants in the soil and sediments are lead and mercury. Ground water contaminants include volatile organic compounds. Under the authority of the EPA and NJDEP, remedial actions at the site are focused on investigating and cleaning up the area. Ground water monitoring at the site is on-going, and Chemours has installed and continues to install vapor mitigation systems at residences within the ground water plume. In addition, Chemours is further assessing ground water conditions. In June 2015, the EPA issued a modification to the site’s RCRA permit that requires Chemours to dredge mercury contamination from a 36-acre area of the lake and remove sediment from two other areas of the lake near the shoreline. The remediation activities commenced when permits and implementation plans were approved in May 2016, and work on the lake dredging project is expected to be complete in 2018.

#### U.S. Smelter and Lead Refinery, Inc. (USS Lead), East Chicago, Indiana

The USS Lead Superfund Site is located in the Calumet neighborhood of East Chicago, Lake County, Indiana. The site includes the former USS Lead facility along with nearby commercial, municipal and residential areas. The primary compounds of interest are lead and arsenic which may be found in soils within the impacted area. The EPA is directing and organizing remediation on this site, and Chemours is one of a number of parties working cooperatively with the EPA on the safe and timely completion of this work. DuPont’s former East Chicago manufacturing facility was located adjacent to the site, and DuPont assigned responsibility for the site to Chemours in the 2015 separation agreement.

The USS Lead site was listed on the National Priorities List (NPL) in 2009. To facilitate negotiations with potentially responsible parties, the EPA divided the residential part of the USS Lead Superfund Site into three zones, referred to as Zone 1, Zone 2, and Zone 3. The division into three zones resulted in Atlantic Richfield Co. and DuPont entering into an agreement in 2014 with the EPA and the State of Indiana to reimburse the EPA’s costs to implement cleanup in Zone 1 and Zone 3. More recently in March 2017, Chemours and three other parties (Atlantic Richfield Co., DuPont, and U.S. Metals Refining Co.) entered into an administrative order of consent to reimburse the EPA’s costs to clean up a portion of Zone 2. According to its website, the EPA is continuing its efforts to identify additional parties who might be potentially responsible for the USS Lead site cleanup, including the remainder of Zone 2. Once it has concluded these efforts, the EPA will engage in negotiations with all known viable and liable parties. The updated environmental accrual for USS Lead is based on the Record of Decision (“ROD”) and Statement of Work currently in place for Zones 1 and 3, as well as the current estimate of Chemours’ share to reimburse the EPA’s Zone 2 cleanup cost under the March 2017 administrative order of consent. The EPA has announced its intent to reconsider the ROD for Zone 1 and the result of that review could increase or decrease Chemours’ future obligations. In addition, there is uncertainty in the outlook for the remainder of Zone 2 given the EPA’s stated objective to identify additional responsible parties.

### PFOA

See discussion under “PFOA” in Note 13 to the Interim Consolidated Financial Statements included in this Quarterly Report on Form 10‑Q.

### Non-GAAP Financial Measures

We prepare our financial statements in accordance with U.S. GAAP. To supplement our financial information presented in accordance with U.S. GAAP, we provide the following non-GAAP financial measures, “Adjusted EBITDA”, “Adjusted Net Income” and “Free Cash Flow”, in order to clarify and provide investors with a better understanding of the Company’s performance when analyzing changes in our underlying business between reporting periods and provide for greater transparency with respect to supplemental information used by management in its financial and operational decision making. We utilize Adjusted EBITDA as the primary measure of segment profitability used by our Chief Operating Decision Maker (CODM).

Adjusted EBITDA is defined as income before taxes excluding the following:

- interest expense, depreciation and amortization,
- non-operating pension and other postretirement employee benefit costs, which represent the components of net periodic pension costs (income) excluding service cost component,
- exchange losses (gains) included in “other income, net” of the statement of operations,
- restructuring, asset-related charges and other charges, net,
- asset impairments,
- losses (gains) on sale of business or assets, and
- other items not considered indicative of our ongoing operational performance and expected to occur infrequently.

Adjusted net income is defined as net income attributable to Chemours adjusted for items excluded from Adjusted EBITDA except interest expense, depreciation and amortization, and certain provision for (benefit from) income taxes. Free Cash Flow is defined as cash provided by (used for) operating activities less cash used for purchases of property, plant and equipment as disclosed in the Consolidated Statements of Cash Flows.

We believe the presentation of these non-GAAP financial measures, when used in conjunction with GAAP financial measures, is a useful financial analysis tool that can assist investors in assessing the Company’s operating performance and underlying prospects. This analysis should not be considered in isolation or as a substitute for analysis of our results as reported under GAAP. In the future, we may incur expenses similar to those eliminated in this presentation. Our presentation of Adjusted EBITDA, Adjusted Net Income and Free Cash Flow should not be construed as an inference that our future results will be unaffected by unusual or infrequently occurring items. The non-GAAP financial measures we use may be defined differently from measures with the same or similar names used by other companies. This analysis, as well as the other information provided in this Quarterly Report on Form 10-Q, should be read in conjunction with the Company’s interim financial statements and notes thereto included in this Quarterly Report, as well as the Company's consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2016.

The following table reconciles Adjusted EBITDA and Adjusted Net Income discussed above to net income attributable to Chemours for the periods presented:

*(Dollars in millions)*

|  | Three Months Ended March 31, 2017 | 2016 |
| --- | ---: | ---: |
| **Net income attributable to Chemours** | $150 | $51 |
| Non-operating pension and other postretirement employee benefit income | (8) | (7) |
| Exchange (gains) losses | (5) | 6 |
| Restructuring charges | 12 | 17 |
| Gain on sale of assets or business | (16) | (89) |
| Transaction costs | — | 3 |
| Legal and other charges 1 | 7 | 5 |
| Provision for income taxes relating to reconciling items 2 | 2 | 25 |
| **Adjusted Net Income** | 142 | 11 |
| Net income attributable to noncontrolling interests | 1 | — |
| Interest expense, net | 51 | 57 |
| Depreciation and amortization | 71 | 66 |
| All remaining provision for (benefit from) income taxes 2 | 20 | (6) |
| **Adjusted EBITDA** | $285 | $128 |

1 Includes litigation settlements, water treatment accruals related to PFOA, and lease termination charges.

2 Total of provision for (benefit from) income taxes reconciles to the amount reported in the Interim Consolidated Statements of Operations for the three months ended March 31, 2017 and 2016.

## Market risk

As filed, 2,920 characters.

We are exposed to changes in foreign currency exchange rates because of our global operations. As a result, we have assets, liabilities and cash flows denominated in a variety of foreign currencies. We are also exposed to changes in the prices of certain commodities that we use in production. Changes in these rates and commodity prices may have an impact on future cash flow and earnings. We manage these risks through normal operating and financing activities and, when deemed appropriate, through the use of derivative financial instruments. We do not enter into derivative financial instruments for trading or speculative purposes.

Chemours enters into foreign currency forward contracts to minimize volatility in earnings related to the foreign exchange gains and losses resulting from remeasuring monetary assets and liabilities that Chemours holds which are denominated in non-functional currencies. These derivatives are stand-alone and have not been designated as a hedge. As of March 31, 2017, we had open foreign exchange forward contracts with an aggregate notional U.S. dollar equivalent of $377 million, the fair value of which amounted to less than $1 million of net unrealized loss.

In a hypothetical adverse change in the market prices or rates that existed at March 31, 2017, a 10% increase in the U.S. dollar against our outstanding hedged contracts on foreign currencies, such as the Euro and Chinese yuan, at the currency exchange rates as of March 31, 2017 would increase our net loss by approximately $4 million, while a 10% depreciation of the U.S. dollar against the same hedged currencies would decrease our net loss by approximately $4 million.

Chemours hedges its net investment in certain European operations. Changes in the fair value of the hedge in the net investment of certain European operations are recorded in accumulated other comprehensive income (loss). For the three months ended March 31, 2017, Chemours did not record any ineffectiveness and recognized a loss of $10 million on its net investment hedges within accumulated other comprehensive income (loss).

Chemours’ risk management programs and the underlying exposure are closely correlated, such that the potential loss in value for the risk management portfolio described above would be largely offset by the change in value of the underlying exposure. See Note 14 to the Interim Consolidated Financial Statements for further information.

### Additional Information

See Part II, Item 7A, “Quantitative and Qualitative Disclosures About Market Risk”, of our Annual Report on Form 10-K for the year ended December 31, 2016 for additional information on the Company’s utilization of financial instruments and an analysis of the sensitivity of these instruments. There have been no material changes in the market risks previously disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016.

## Controls and procedures

As filed, 1,442 characters.

### Disclosure Controls and Procedures

The Company maintains disclosure controls and procedures designed to provide reasonable assurance that information required to be disclosed in the Company’s reports filed or submitted under the Securities Exchange Act of 1934 (Exchange Act) is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission. These controls and procedures also provide reasonable assurance that information required to be disclosed in such reports is accumulated and communicated to management, including its Chief Executive Officer (CEO) and Chief Financial Officer (CFO), to allow timely decisions regarding required disclosures.

As of March 31, 2017, the Company’s CEO and CFO, together with management, conducted an evaluation of the effectiveness of the Company’s disclosure controls and procedures as defined in Rule 13a-15(e) under the Exchange Act. Based on that evaluation, the CEO and CFO have concluded that these disclosure controls and procedures are effective at the reasonable assurance level.

### Changes in Internal Control over Financial Reporting

There have been no changes in the Company's internal control over financial reporting that occurred during the quarter ended March 31, 2017 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

## Risk factors

As filed, 137 characters.

There have been no material changes to the risk factors disclosed in our Annual Report on Form 10-K for the year ended December 31, 2016.

Filed May 3, 2017.
Source: SEC EDGAR, the filing index for accession 0001564590-17-008323. Last ingested by Listed: Nov 5, 2026, 19:57 ET. No prices; not investment advice.
